CHMFL-ALK/EGFR-050

N/A

Report date: 2026/05/08 20:02:52
NME

Base Information

Drug NameCHMFL-ALK/EGFR-050
Drug Alias NameCHMFL-ALK/EGFR-050
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAnaplastic lymphoma kinase inhibitorsEpidermal growth factor receptor erbB1 inhibitors
TargetsEpidermal growth factor receptor erbB1Anaplastic lymphoma kinase
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHefei Academy Of Physical Sciences, Chinese Academy Of Sciences
China Registration ClassN/A

Develop Information

Active CompaniesHefei Academy Of Physical Sciences, Chinese Academy Of Sciences
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A